Application of a new multinomial phase II stopping rule using response and early progression

Journal of Clinical Oncology

Volumn 19, Issue 3, 2001, Pages 785-791

  Dent, S ^a   Zee, B ^a   Dancey, J ^a   Hanauske, A ^a   Wanders, J ^a   Eisenhauer, E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CARCINOMA; CANCER GROWTH; CANCER RESEARCH; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG SCREENING; HUMAN; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0035253728     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.3.785     Document Type: Article

References (6)

1. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent
2. One-sample multiple testing procedure for phase II clinical trials
3. Optimal two-stage designs for phase II clinical trials
4. How large should a phase II trial of a new drug be?
5. Multinomial phase II cancer trials incorporating response and early progression
6. Progressive disease rate as a surrogate endpoint of phase II trials for non-small cell lung cancer